The PIAS proteins (Protein Inhibitor of Activated STATs) constitute a family of multifunctional nuclear proteins operating as SUMO E3 ligases and being involved in a multitude of interactions. They participate in a range of biological processes, also beyond their well-established role in the immune system and cytokine signalling. They act both as transcriptional corepressors and coactivators depending on the context. In the present work, we investigated mechanisms by which PIAS1 causes activation or repression of c-Myb dependent target genes. Analysis of global expression data shows that c-Myb and PIAS1 knockdowns affect a subset of common targets, but with a dual outcome consistent with a role of PIAS1 as either a corepressor or coactivator. Our mechanistic studies show that PIAS1 engages in a novel interaction with the acetyltransferase and coactivator p300. Interaction and ChIP analysis suggest a bridging function where PIAS1 enhances p300 recruitment to c-Myb-bound sites through interaction with both proteins. In addition, the E3 activity of PIAS1 enhances further its coactivation. Remarkably, the SUMO status of c-Myb had a decisive role, indicating a SUMO-dependent switch in the way PIAS1 affects c-Myb, either as a coactivator or corepressor. Removal of the two major SUMO-conjugation sites in c-Myb (2KR mutant), which enhances its activity significantly, turned PIAS1 into a corepressor. Also, p300 was less efficiently recruited to chromatin by c-Myb-2KR. We propose that PIAS1 acts as a "protein inhibitor of activated c-Myb" in the absence of SUMOylation while, in its presence, PIAS behaves as a "protein activator of repressed c-Myb".

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbagrm.2016.03.011DOI Listing

Publication Analysis

Top Keywords

pias1
10
coactivator corepressor
8
c-myb dependent
8
inhibitor activated
8
pias1 corepressor
8
pias1 enhances
8
c-myb
6
pias1 binds
4
p300
4
binds p300
4

Similar Publications

Correction: Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT1.

Mol Cancer

December 2024

Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009, China.

View Article and Find Full Text PDF

Background: Cancer remains one of the leading causes of mortality worldwide, characterized by uncontrolled cell proliferation and metastasis. Protein Inhibitor of Activated STAT (PIAS) family genes, comprising PIAS1, PIAS2, PIAS3, and PIAS4, are emerging as significant players in cancer biology due to their roles in SUMOylation, transcriptional regulation, and modulation of signal transduction pathways. This study provides a comprehensive analysis of PIAS family genes from a pan-cancer viewpoint.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the genetic connections between endometrial cancer (EC), endometriosis (ENDO), and obesity (OBY) to identify potential therapeutic targets by analyzing gene expression data.
  • - A total of 26 shared differentially expressed genes were found, with IGF-1, CREBBP, EP300, and PIAS1 being key genes linked to disease mechanisms and survival outcomes.
  • - Elevated IGF-1 levels in EC patients are associated with worse survival rates, indicating it may serve as a prognostic marker and highlighting the need for targeted therapies based on genetic findings.
View Article and Find Full Text PDF

ZNF350 gene polymorphisms promote the response to Peg-IFNα therapy through JAK-STAT signaling pathway in patients with chronic hepatitis B.

Front Immunol

November 2024

Department of Laboratory Medicine, Fujian Key Laboratory of Laboratory Medicine, Gene Diagnosis Research Center, Fujian Clinical Research Center for Clinical Immunology Laboratory Test, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Background: The varying individual responses to Pegylated interferon-α (Peg-IFNα) in patients with chronic hepatitis B (CHB) pose significant hurdles in treatment optimization, and the underlying mechanisms remain unclear.

Objective: We aimed to identify genetic polymorphisms influencing the efficacy of Peg-IFNα in patients with HBeAg-positive CHB, with the goal to predict Peg-IFNα response before treatment.

Methods: We employed an Asian Screening Array analysis involving 124 HBeAg-positive CHB patients treated with Peg-IFNα.

View Article and Find Full Text PDF

Computational insights into irinotecan's interaction with UBE2I in ovarian and endometrial cancers.

Comput Biol Chem

December 2024

Laboratory of Integrative Genomics, Department of Integrative Biology, School of BioSciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu 632014, India. Electronic address:

Endometrial and Ovarian cancers are two highly prevalent and fatal reproductive diseases with poor prognoses among women. Elevated estrogen levels in Ovarian Cancer (OC) stimulate the endometrium, causing Endometrial Cancer (EC). Although numerous studies have reported the crucial genes and pathways in this cancer, the pathogenesis of this disease remains unclear.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!